

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):



BLACK BORDERS

- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: 0 552 624 A1

(22)

EUROPEAN PATENT APPLICATION

(21) Application number: 93100257.0

(51) Int. Cl. 5: A61K 31/20, A61K 31/07

(22) Date of filing: 11.01.93

(30) Priority: 22.01.92 US 823741
22.01.92 US 823786
22.01.92 US 823928
23.01.92 US 824647

(43) Date of publication of application:
28.07.93 Bulletin 93/30

(46) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(71) Applicant: F. HOFFMANN-LA ROCHE AG
Postfach 3255
CH-4002 Basel(CH)

(72) Inventor: Bollag, Werner
10 Mythenstrasse
CH-4054 Basle(CH)
Inventor: Grippo, Joseph Francis
63 Woodstone Road
Basking Ridge, N.J. 07920(US)
Inventor: Levin, Arthur
132 Stonehouse Road
Glen Ridge, N.J. 07028(US)

(74) Representative: Grossner, Lutz, Dr. et al
Grenzacher Strasse 124 Postfach 3255
CH-4002 Basel (CH)

(54) Pharmaceutical compositions containing 9-cis retinoic acid, salts and esters thereof.

(57) 9-cis retinoic acid, its salts and esters can be used in the treatment of malignant and premalignant epithelial lesions, skin photodamage, disorders caused by increased sebum production, and psoriasis.

EP 0 552 624 A1

The present invention is concerned with novel pharmaceutical compositions containing 9-cis retinoic acid, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof.

Furthermore, the invention is concerned with 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament.

- 5 In another aspect, the invention is concerned with the use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters in the manufacture of a medicament for medical indications as defined below.

In accordance with this invention, it has been found that 9-cis retinoic acid, its pharmaceutically acceptable salts or its pharmaceutically acceptable hydrolyzable esters possess with regard to epithelial lesions, antihyperplastic, antimetaplastic, antineoplastic tumor-preventative and tumor-therapeutic properties exhibiting limited toxicity or other adverse effects associated with retinoids. It has now been found that pathological conditions treatment of which involves the above properties can be effectively treated by administering 9-cis retinoic acid, its pharmaceutically acceptable salts or its pharmaceutically acceptable hydrolyzable esters either systemically or topically.

- 10 15 In accordance with one embodiment of this invention, 9-cis retinoic acid, its pharmaceutically acceptable salt or its pharmaceutically acceptable hydrolyzable esters when administered to mammals having premalignant epithelial lesions, i.e., precancerous lesions, retards the progression of the lesions. This compound controls the cellular growth and differentiation of these premalignant or precancerous lesions and causes cellular repair. In this way, the development of these lesions into epithelial carcinomas is prevented.

20 25 In treating premalignant or precancerous epithelial lesions to retard the progression of these lesions into carcinomas, 9-cis retinoic acid, its pharmaceutically acceptable salts or its pharmaceutically acceptable hydrolyzable esters is administered either orally or topically to patients affected by these lesions in an amount effective for retarding the progression of these lesions. The amount will be dependent on the amount and size of the lesions and on the requirement of the patient.

- 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

The treatment of precancerous lesions and malignant tumors of epithelial nature can be effected with 9-cis retinoic acid its pharmaceutically acceptable salts or its pharmaceutically acceptable hydrolyzable esters alone or in combination with other measures such as surgery, radiation therapy, hormone therapy or treatment with standard chemotherapy (cytostatic and cytotoxic agents) or biological response modifiers (interferons, interleukins or other cytokines).

Furthermore, in accordance with this invention, it has been found that 9-cis retinoic acid and pharmaceutically acceptable salts and hydrolyzable esters thereof applied topically to the skin of a patient reverses the conditions associated with photodamage. Hence, by the topical application of compounds of formula I to the skin of patients which has been damaged through sun exposure, the effects of wrinkling, elastosis and premature aging can be reversed leading to an improvement in the appearance of the skin.

Through the topical administration of the compounds of the formula I and pharmaceutically acceptable salts and hydrolyzable esters, the acceleration of repair of dermal damage is accomplished so as to provide the skin with a smoother and younger appearance.

In accordance with this invention, it has also been found that when 9-cis retinoic acid its pharmaceutically acceptable salts, or its pharmaceutically acceptable hydrolyzable esters is administered either orally or topically to patients sebum secretion is reduced. Therefore, the administration of this compound which acts to reduce sebum secretion and acne lesions provides a means for combatting diseases such as acne, oily hair and oily scalp. In such a manner, the administration of this compound may be used either as a prophylaxis against disorders caused by excess sebum secretion such as acne or oily scalp and hair or in their treatment.

It is known that inhibition of sebum production and/or secretion is effective in the treatment and/or prevention of disorders such as acne. Increased sebum secretion may result in such dermatological conditions as seborrhea, including dandruff, oily skin, oily hair, whiteheads and blackheads.

In accordance with this invention, the topical and oral administration of the compound of formula I, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters are effective in treating all forms of acne such as inflammatory and non-inflammatory.

In yet another aspect of this invention it has been found that 9-cis retinoic acid, its pharmaceutically acceptable salts, or its pharmaceutically acceptable hydrolyzable esters when administered either orally or topically to patients suffering from psoriasis, it is effective in treating psoriasis. This administration reduces the effects on the skin of the disease psoriasis.

The pharmaceutically acceptable salts include any salt chemically permissible for 9-cis retinoic acid and applicable to human patients in a pharmaceutically acceptable preparation. Any such conventional pharmaceutically acceptable salt can be utilized. Among the conventional salts which can be utilized there are the base salts included, for example, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium, and ammonium or alkyl ammonium salts.

In accordance with this invention the 9-cis retinoic acid can be administered in the form of its pharmaceutically acceptable hydrolyzable esters. Any pharmaceutically acceptable hydrolyzable ester can be used in the compositions and methods of this invention. Among the esters are the aromatic esters such as benzyl (OBzl) or benzyl substituted with lower alkyl, halo, nitro; or lower alkyl, e.g., t-butyl; or cyclopentyl, cyclohexyl, cycloheptyl; or 9-fluorenylmethyl.

In accordance with this invention, 9-cis retinoic acid or its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters can be provided in pharmaceutically acceptable oral, or topical composition. These pharmaceutical compositions of the invention contain said 9-cis retinoic acid or its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters in association with a compatible pharmaceutically acceptable carrier material. Any conventional carrier material can be utilized. The carrier material can be an organic or inorganic inert carrier material suitable for oral administration. Suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene-glycols, petroleum jelly and the like. Furthermore, the pharmaceutical preparations may contain other pharmaceutically active agents. Additional additives such as flavoring agents, preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding.

The pharmaceutical preparations can be made up in any conventional form including: (a) a solid form for oral administration such as tablets, capsules, pills, powders, granules, and the like; and (b) preparations for topical administrations such as solutions, suspensions, ointments, creams, gels, micronized powders, aerosols and the like. The pharmaceutical preparations may be sterilized and/or may contain adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, salts for varying the osmotic pressure and/or buffers.

For topical administration to the skin the aforementioned compound is preferably prepared as ointments, tinctures, creams, gels, solutions, lotions, sprays, suspensions, shampoos, hair soaps, perfumes and the like. In fact, any conventional composition utilized for application to the scalp or skin can be utilized in accordance with this invention. Among the preferred methods of applying the composition containing the agents of this invention is in the form of a gel, lotion and cream. The pharmaceutical preparation for topical administration to the skin can be prepared by mixing the aforementioned active ingredient with non-toxic, therapeutically inert, solid or liquid carriers customarily used in such preparations. These preparations should contain at least about 0.01 percent by weight, of the active ingredient based upon the total weight of the composition. Since the active ingredient, 9-cis retinoic acid is relatively non-toxic and non-irritating it may be used in topical compositions in amounts exceeding 0.15% percent. It is preferred that these preparations contain about 0.01 to 0.15% percent by weight of the active ingredient based upon the total weight of the composition. It is also preferred to apply these preparations once or twice daily to the skin. These preparations can be applied according to the need of the patient. In carrying out this invention, the active ingredient can be applied in an aqueous solution or an alcohol solution such as ethyl alcohol.

In preparing the topical preparations described above additives such as preservatives, thickeners, perfumes and the like conventional in the art of pharmaceutical compounding of topical preparation can be used. In addition, conventional antioxidants or mixtures of conventional antioxidants can be incorporated into the topical preparations containing the aforementioned active agent. Among the conventional antioxidants which can be utilized in these preparations are included N-methyl- α -tocopherolamine, tocopherols, butylated hydroxyanisole, butylated hydroxytoluene, ethoxyquin and the like. Cream-base pharmaceutical formulations containing the active agent, used in accordance with this invention, are composed of aqueous emulsions containing a fatty acid alcohol, semi-solid petroleum hydrocarbon, 1,2-ethyleneglycol and an emulsifying agent.

Ointment formulations containing the active agent in accordance with this invention comprise admixtures of a semi-solid petroleum hydrocarbon with a solvent dispersion of the active material. Cream compositions containing the active ingredient for use in this invention preferably comprise emulsions formed from a water phase of a humectant, a viscosity stabilizer and water, an oil phase of a fatty acid alcohol, a semi-solid petroleum hydrocarbon and an emulsifying agent and a phase containing the active agent dispersed in an aqueous stabilizer-buffer solution. Stabilizers may be added to the topical preparation. Any conventional stabilizer can be utilized in accordance with this invention. In the oil phase, fatty acid alcohol components function as a stabilizer. These fatty acid alcohol components are derived from the reduction of a long-chain saturated fatty acid of at least about 14 carbon atoms. Also, conventional perfumes and lotions generally utilized in topical preparation for the hair can be utilized in accordance with this invention. Furthermore, if desired, conventional emulsifying agents can be utilized in the topical preparations of this invention.

A preferred oral dosage form comprises tablets, capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract. The oral dosages contemplated in accordance with the present invention will vary in accordance with the needs of the individual patient as determined by the prescribing physician. Generally, however, a daily dosage of from about 0.01 mg to about 3 mg per kg of body weight and preferably from about 0.025 mg to about 1.5 mg per kg of body weight of the patient is utilized. This dosage may be administered according to any dosage schedule determined by the physician in accordance with the requirements of the patient.

It is likewise within the purview of the present invention to incorporate the therapeutically active substance enumerated herein in any desired amount for enteral administration within the oral unit dosage form. It is preferred, however, to formulate preparations containing the active substance of the present invention in such a manner that each dose forms contains from about 1 mg to about 50 mg with suitable therapeutically inert fillers and diluents. It is especially preferred to incorporate such a dosage into soft gelatin capsules and tablets.

The efficacy of 9-cis retinoic acid in the use in accordance with this invention can be demonstrated in test models as described below.

A. Antitumor effects of 9-cis retinoic acid on human tumor cell lines and on experimental tumor

Inhibitory effect on growth and proliferation of human transformed epithelial cell lines

9-cis retinoic acid was tested on the human tumor cell lines SCC 15 (squamous cell carcinoma of the tongue) and A 431 (squamous cell carcinoma of the vulva). Proliferation was measured by the capacity of viable cells to reduce MTT dye [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] by a mitochon-

drial enzymatic activity (Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. *J. Immunol. Methods* 65: 55-63, 1983).

Results

5

Human squamous cell carcinoma SCC 15 (tongue)

10

- Viable cells in % of controls after 7 days of incubation	
Controls (DMSO)	100 ± 11.4
9-cis retinoic acid ($3 \cdot 10^{-7}$ M)	54 ± 7.5 p < 0.0025
interferon α (IFN α) (1000 U/ml)	60 ± 8.3 p < 0.005
9-cis retinoic acid + IFN α	20 ± 2.5 p < 0.001

15

9-cis retinoic acid in a concentration of $3 \cdot 10^{-7}$ M inhibited proliferation by 46%, in combination with IFN α even by 80%.

20

Human squamous cell carcinoma A 431 (vulva)

25

- Viable cells in % of controls after 7 days of incubation	
Controls (DMSO)	100 ± 8.7
9-cis retinoic acid ($3 \cdot 10^{-7}$ M)	36 ± 1.8 p < 0.001
IFN α (1000 U/ml)	42 ± 0.9 p < 0.0005
9-cis retinoic acid + IFN α	23 ± 1.4 p < 0.001

30

9-cis retinoic acid in a concentration of $3 \cdot 10^{-7}$ M inhibited proliferation by 64%, in combination with IFN α even by 77%.

9-cis retinoic acid had a marked growth-inhibitory effect on the two tested human epithelial cancer cell lines.

35

9-cis retinoic acid was further investigated on its effect on other transformed cell lines. A proliferation assay was performed on a virus containing cell line. SKV-11, a transformed keratinocyte cell line containing human papilloma virus 16 (HPV 16) was tested with regard to inhibition of proliferation by 9-cis retinoic acid in two experiments with four replicates. $5 \cdot 10^4$ cells/well were plated in Eagle's medium and incubated for 2 days. Direct cell counting with a hemocytometer was done before and after incubation with the retinoid in a concentration of 10^{-6} M and in corresponding DMSO controls. Growth inhibition was expressed in % compared to controls.

Result: 9-cis retinoic acid in a concentration of 10^{-6} M significantly inhibited proliferation of the human transformed keratinocytes SKV-11 by 32.4% (p < 0.001).

B. Effect of 9-cis retinoic acid on tumor cell induced angiogenesis

45

It is now well established that unrestricted growth of tumors is dependent on angiogenesis. Increase in tumor cell population must be preceded by an increase in new capillaries that converge upon the tumor. Therefore by inhibiting angiogenesis, tumor growth is inhibited (Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. *Cancer Res.* 46: 467-473, 1986; Sidky YA and Borden EC. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. *Cancer Res.* 47: 5155-5161, 1987).

The angiogenesis assays have been previously described (Sidky YA and Auerbach R. Lymphocyte induced angiogenesis: A quantitative and sensitive assay of the graft-vs-host reaction. *J. exp Med* 141: 1084-1100, 1975. Majewski S et al. Inhibition of tumour-induced angiogenesis by systemically administered protamine sulphate. *Int J Cancer* 33: 831-833, 1984). Two assays were used in testing 9-cis retinoic acid. In the first assay the retinoid was added in vitro to the cell line before being injected into mice. In the second assay the mice were injected intraperitoneally with the retinoid in vivo before the tumor cell line was injected intradermally.

- Method: Cells of two tumorigenic cell lines, SKv-e2 and HeLa, and of a non-tumorigenic cell line, SKv-e1 were preincubated in vitro for 48 hours with 9-cis retinoic acid at a concentration of 10^{-7} M followed by cell counting and washing in TC 199 medium. The cell concentration was adjusted to $2 \cdot 10^5$ viable cells per 0.1 ml of medium and injected intradermally into X-ray irradiated, but not retinoid-treated Balb/c mice.
- 5 Controls were injected with tumor cells preincubated with DMSO. The angiogenic effect was determined according to the methods referred to above.

Results

- 10 a) Effect of in vitro preincubation with 9-cis retinoic acid on angiogenic capacity of the cell lines SKv-e2 (tumorigenic), HeLa (tumorigenic) and SKv-e1 (non-tumorigenic), in Balb/c mice

Mean number of blood vessels			
	SKv-e2	HeLa	SKv-e1
Controls	34.7±3.7	32.5±2.7	26.3±1.5
9-cis retinoic acid	23.6±4.2 p < 0.001	23.8±2.9 p < 0.001	25.6±2.2 p < 0.1

20 In contrast to the inhibitory effect of 9-cis retinoic acid on the formation of new blood vessels induced by the two tumorigenic cell lines, 9-cis retinoic acid did not inhibit angiogenesis induced by the non-tumorigenic subline.

- 25 b) Inhibition of cell-induced angiogenic effect by pretreatment of Balb/c mice in vivo by 9-cis retinoic acid.

Mean number of blood vessels			
	Control	9-cis retinoic acid	
HeLa (Tumorigenic)	28.3 ± 0.8	16.3 ± 1.8	p < 0.001
SKv-I2 (Tumorigenic)	30.3 ± 2.6	15.3 ± 1.0	p < 0.001
SKv-e2 (Tumorigenic)	31.3 ± 2.7	19.7 ± 0.6	p < 0.001
SKv-e1 (Non-Tumorigenic)	19.7 ± 3.7	24.3 ± 5.6	p > 0.1

30 Mice treated with 9-cis retinoic acid showed an inhibition of new blood vessel formation when injected with cells of 3 tumorigenic cell lines. There was no anti-angiogenic effect when a non-tumorigenic cell line was used.

- 35 40 9-cis retinoic acid inhibits in vitro and in vivo the formation of new blood vessels induced by tumor cell lines. Since neovascularisation is a prerequisite for tumor growth, 9-cis retinoic acid acts not only by a direct antitumor effect via inhibition of proliferation and/or induction of differentiation but also by an anti-angiogenic effect, inhibiting indirectly tumor growth.

C. Effect of 9-cis retinoic acid on chemically-induced skin papillomas in mice

- 45 The preventive and therapeutic effect of retinoids on chemically-induced tumors of the skin, of the respiratory, digestive and urinary tract as well as of the mammary gland is well established (Bollag W. and Hartmann HR. Prevention and therapy of cancer with retinoids in animal and man. Cancer Surveys 2: 293-314, 1983). 9-cis retinoic acid has a marked therapeutic effect on established skin papillomas of mice leading to regression of these epithelial tumors. The papilloma test is a standard test for the anti-tumor screening of retinoids.

Results

Dose 5 mg/kg i.p.	Percent change in the average sum of the papilloma diameters per mouse	
10 Controls	+ 23.5 ± 2.1	
15 9-cis retinoid acid	400	- 43.3 ± 2.4 p < 0.0005
	200	- 24.8 ± 4.5 p < 0.0005

9-cis retinoic acid had a substantial therapeutic antitumor effect on established chemically-induced skin papillomas of mice, producing regression of this epithelial tumor.

20 D. Effect of 9-cis retinoic acid on antipsoriatic activity

The antipsoriatic activity can be determined by the capacity to produce a regression of chemically-induced skin papillomas in mice in the test model quoted in paragraph C. The papilloma test is a standard 25 test for the antipsoriatic effect of retinoids (Teelmann K, Bollag W. The relevance of the mouse papilloma test as a predictor of retinoid activity in human psoriasis. Dermatologica 180: 30-35, 1990).

As can be seen from the data given in paragraph C, 9-cis retinoic acid has a marked therapeutic effect in this model for predicting antipsoriatic activity in humans.

30 E. Activity of 9-cis retinoic acid in acne and sebum suppression

The etiology of acne is multifactorial, with excessive sebum secretion, hyperkeratinization, and bacterial colonization playing key roles in its pathology.

The following two models have been used as a measure for anti-acne activity:

- 35 1. The human sebocyte antiproliferation assay has been shown to correlate strongly with compounds examined clinically in humans for acne (Doran T.I. and Shapiro S.S. Retinoid effects on sebocyte proliferation. In "Retinoids, Part B. Cell Differentiation and Clinical Applications". Methods in Enzymology, Volume 190. Ed. L. Packer, Academic Press, pp. 334-338, 1990).
- 40 2. The rhino mouse antikeratinizing assay has also been used as a measure of anti-acne activity (Mezick J.A., Bhatia M.C., and Capetola R.J. Topical and systemic effects of retinoids on horn-filled utriculus size in the rhino mouse. A model to quantify "antikeratinizing" effects of retinoids. J Invest Dermatol 83, 110-113, 1984. Mezick J.A., Bhatia M.C., Shea L.M., Thorne E.G., and Capetola R.J. Anti-acne activity of retinoids in the Rhino-mouse. In: Models of Dermatology, Maibach and Lowe (eds), Karger (Basel), volume 2, pp. 59-63, 1985).

45 1. Sebocyte Proliferation

I. Method

50 Sebaceous cells were isolated from adult human sebaceous glands, derived from facial skin removed during cosmetic surgery, and cultured on a layer of mouse 3T3 fibroblasts (Doran T.I., Baff R., Jacobs P., and Pacia E. Characterization of human sebaceous cells in vitro. J Invest Dermatol 96, 341-348, 1991). Cells were plated in medium without the test compound and then given test compound in fresh medium 24-48 hours after the initial plating. The cultures were given fresh medium, containing the test compound, every 55 48 hours. On the day of harvesting, the cultures were rinsed with 0.03% EDTA in PBS, to remove only the 3T3 fibroblasts, followed by incubation in 0.05% trypsin/0.03% EDTA. The cells were suspended, mixed vigorously to prepare a single cell suspension and counted in a hemocytometer. Results were determined as the amount of compound necessary to inhibit the proliferation of sebaceous cells by 50% (IC_{50}) in μM

as compared to a control culture which was treated only with diluent.

II. Results

5 9-cis retinoic acid was active in vitro in suppressing the proliferation of human sebocytes with an IC₅₀ of 0.1 μM.

2. Rhino Mouse Utricle Reduction, Antikeratinizing Assay

10 I. Method

Female rhino mice (*hr/hr*), 6 to 8 weeks of age, were obtained from Jackson Laboratories. Six animals per group were used. Compounds were prepared by dissolving them in acetone. The test compounds were applied to the dorsa of the mice with a micropipette. 100 μl of the test material was applied daily for 5 days for 3 consecutive weeks. The mice were sacrificed by CO₂ inhalation. A flap of skin from the dorsa was cut out and saved for histological examination. The epidermis, separated from the dermis, was placed in wire mesh histological cassettes and dehydrated in: 70%, 80%, 95%, 100% ethanol, and xylene for 2 hours at each stage. The skin samples were removed from the xylene bath and mounted on glass microscope slides. Image analysis using the Ultimage system was used to determine the mean area of the utricles. Approximately 150 utricles per mouse were analyzed.

II. Results

Effect of 9-cis retinoic acid in Reducing Rhino Mouse Utricle Size after Topical Application for Three Weeks

25

Compound	Dose		Utricle Size (Sq. Microns) (Mean ± SD)	% Change
	(% Solution)	(mg/kg)		
9-cis retinoic acid	0.001%	0.04	2593 ± 559	-52
	0.01%	0.4	1425 ± 167	-74
	0.1%	4.0	1210 ± 76	-78
Control	Vehicle		5420 ± 42	---

30 All p values were < 0.001 for comparison of compound-treated to vehicle-treated groups. Student's t-test was performed for statistical determination.

35 9-cis retinoic acid was active in this antikeratinizing and anti-acne assay.

40 F. Clinical data on the treatment of acne vulgaris patients with 9-cis retinoic acid

45 8 patients, 2 males and 6 females, 15 to 48 years old, with an average age of 27 years, have been treated with 9-cis retinoic acid during 1 to 3 months. Of the 8 patients, 2 were treated for 1 month, 2 for 2 months and 4 for 3 months. 5 patients had comedones, 7 had papules, 6 had pustules and 1 had nodules. 7 patients had lesions only in the face, 1 patient had lesions in the face and on the back. 9-cis retinoic acid was given in the following formulation: 0.01% of the active compound in a solution of ethanol-propylene glycol (50/50). The solution was applied once a day, in the evening, to the regions where acne lesions were present.

50 55 Lesions (comedones, papules, pustules and nodules) were counted separately at baseline and after 1, 2 and 3 months of treatment. The percentage of decrease of total lesion count from the baseline count was determined for every patient and the mean value was calculated. The results are as follows: After 1 month the total lesion count (8 patients) had decreased by an average of 48% after 2 months (6 patients) by 72% and after 3 months (4 patients) by 77%. Particular attention was paid to irritation of the skin. In 2 patients, at the beginning of treatment a slight erythema and slight scaling was observed which was transient and disappeared within one to two weeks in spite of continuation of treatment. The patients hardly took notice of these side effects.

55 Treatment of acne with 9-cis retinoic acid yielded very good results, comparable to those achieved with all-trans or 13-cis retinoic acid. The drug concentration needed for a successful topical therapy was 0.01%

and is markedly lower than that of all-trans retinoic acid or 13-cis retinoic acid where a concentration of 0.05% is necessary to achieve the same therapeutic result. Furthermore the therapeutically efficacious concentration of 9-cis retinoic acid does induce substantially fewer side effects than that of all-trans or 13-cis retinoic acid.

5

G. Activity of 9-cis retinoic acid in photodamage

I. Methods

10 Hairless mice were UVB irradiated, and, thereafter, treated topically with 9-cis retinoic acid to effect repair of the dermal damage.

Skin from the irradiated and treated area was histologically evaluated for the extent of repair. Repair was defined by the appearance of a normalized dermis extending from the epidermis down to the layer of compressed elastin. The extent of repair was reflected by the width of this zone.

15 The methods are described in: Bryce G.F., Bogdan N.J., Brown C.C. Retinoic acids promote the repair of the dermal damage and the effacement of wrinkles in the UVB-irradiated hairless mouse. J. Invest. Dermatol. 91, 175-180, 1988.

II. Results

20

	Treatment	Repair	Wrinkling
		Area in mm ² x 10 ⁻³	Scale 0-4
		ED ₅₀	ED ₅₀
25	Control	0.21 ± 0.12	3.1 ± 0.3
30	9-cis retinoic acid		
	10 µg	0.57 ± 0.48	2.6 ± 0.7
	30 µg	0.87 ± 0.34	1.8 ± 0.3 **
	100 µg	7.37 ± 2.04 **	0.3 ± 0.1 ***
35	200 µg	6.46 ± 1.57 **	0 ***

** p < 0.01

*** p < 0.001 vs control

40

H. Acute Toxicity

Acute Toxicity was determined in Füllinsdorf albino mice. 9-cis retinoic acid was suspended in rape oil and administered intraperitoneally in one single dose. The lethal dose (LD) of 10%, 50% and 90% of the mice was recorded 24 hours, 10 days and 20 days after the application of the single dose. For each group 10 mice were used.

Results (in mg/kg of the administered compound)

50

	24 hours	10 days	20 days	
55	LD 10%	> 4000	1200	1200
	LD 50%	> 4000	1400	1400
	LD 90%	> 4000	1800	1800

The following examples illustrate pharmaceutical preparations containing the 9-cis retinoic acid as provided by the present invention. The compound 9-cis retinoic acid can also be designated by the name

EP 0 552 624 A1

(E,Z,E,E)-3,7-dimethyl-9-[2,6,6-trimethyl-1-cyclohexen-1-yl]-2,4,6,8-nonatetraenoic acid.

Example 1

5

Lotion (solution)		preferred
9-cis Retinoic Acid	0.02 - 0.30 g	
Propylene Glycol	5.00 - 20.00 g	10.00 g
PEG-Glyceryl Cocoate *	0.00 - 20.00 g	10.00 g
dl- α -Tocopherol	0.001 - 0.50 g	0.02 g
Ascorbyl Palmitate	0.01 - 0.20 g	0.10 g
Propyl Gallate	0.001 - 0.02 g	0.002 g
Citric acid, anhydr **	0.00 - 0.20 g	0.01 g
Isopropanol ***	40.00 - 90.00 g	50.00 g
Water, ad	100.00 g	100.00 g (resp. ml)

* or other tensides

** or other complexing agents e.g. EDTA

*** or other alcohols e.g., Ethanol

20

Example 2

25

Gel		preferred
9-cis Retinoic Acid	0.02 - 0.30 g	
Propylene Glycol	5.00 - 20.00 g	10.00 g
PEG-Glyceryl Cocoate *	0.00 - 20.00 g	10.00 g
dl- α -Tocopherol	0.001 - 0.50 g	0.02 g
Ascorbyl Palmitate	0.01 - 0.20 g	0.10 g
Propyl Gallate	0.001 - 0.02 g	0.002 g
Citric acid, anhydr **	0.00 - 0.20 g	0.01 g
Isopropanol ***	40.00 - 90.00 g	50.00 g
HPMC ****	0.50 - 5.00 g	3.00 g
Preservative *****	q.s.	q.s.
Water, ad	100.00 g	100.00 g

* or other tensides

** or other complexing agents e.g. EDTA

*** or other alcohols e.g., Ethanol

**** Hydroxypropyl Methylcellulose or other polymers e.g. neutralized

Carbomer, Methyl Cellulose, Sodium. Carboxymethylcellulose

***** Preservatives e.g., Paraben esters (methyl, ethyl, propyl, butyl), Sorbic

Acid, Benzoic Acid

40

50

55

Example 3Cream

		<u>preferred</u>
5	9-cis Retinoic Acid	0.02 - 0.30 g
10	Glycerol	0.00 - 10.00 g 5.00 g
15	Na ₂ EDTA	0.001 - 0.50 g 0.03 g
20	Glycerides *	5.00 - 20.00 g 10.00 g
25	Cetyl Alcohol	0.50 - 5.00 g 1.00 g
30	Stearyl Alcohol	0.50 - 5.00 g 1.00 g
35	Glycerol mono Stearate	1.00 - 8.00 g 4.00 g
40	Ceteareth **	0.50 - 5.00 g 2.00 g
45	dl- α -Tocopherol	0.001 - 0.50 g 0.02 g
50	Preservative ***	q.s. q.s.
55	Water, ad	100.00 g 100.00 g

* e.g. Caprylic/Capric/Triglyceride, Caprylic/Capric/Linoleic Triglyceride, natural glycerides, as well as e.g., Propylene Glycol, Dicaprylate/Dicaprante and waxes such as Stearyl Stearate, Oleyl Oleate, Isopropyl Myristate.

** Ceteareth 5-30, or other emulsifiers such as Polysorbate 20-80, Sorbitane esters of fatty acids, fatty acid esters of PEG.

*** Preservatives e.g., Paraben esters (methyl, ethyl, propyl, butyl), Sorbic Acid, Benzoic Acid.

Example 4

Fill mass for soft gelatin capsules	
9-cis Retinoic Acid	5.00 - 50.00 mg
Oil *	1 - 3 parts
Wax mixture **	1 - 5 parts
Fill volume	1 - 6 minims

* natural vegetable oils, e.g., soy oil, peanut oil, and artificial glycerides

** composition of natural and artificial waxes or partially hydrated fats

Example 51. Hard Gelatine capsules containing 20 mg active substance:

5 Composition: One Capsule contains:

10	9-cis Retinoic acid Gelatine Bloom 30 Maltodextrin MD 05 dl- α -Tocopherol Sodium ascorbate Microcrystalline cellulose Magnesium stearate (weight capsule content)	20.0 mg 70.0 mg 108.0 mg 2.0 mg 10.0 mg 48.0 mg 2.0 mg 260.0 mg
15		

Procedure:

20 The active substance is wet milled in a solution of gelatine, maltodextrin, dl- α -Tocopherol and sodium ascorbate.

The wet milled suspension is spray-dried.

The spray-dried powder is mixed with microcrystalline cellulose and magnesium stearate.

25 260 mg each of this mixture are filled into hard gelatine capsules of suitable size and color.

Example 62. Tablet containing 20 mg active substance:

30 Composition:

35	Tablet kernel:	
	9-cis Retinoic acid Anhydrous lactose Microcrystalline cellulose dl- α -Tocopherol Sodium ascorbate Polyvinylpyrrolidone K30 Magnesium stearate (Kernel weight)	20.0 mg 130.5 mg 80.0 mg 2.0 mg 10.0 mg 5.0 mg 2.5 mg 250.0 mg
40		

45	Film coat:	
	9Hydroxypropyl methylcellulose Polyethyleneglycol 6000 Talc Iron oxide, yellow Titanium dioxide (weight of the film)	3.5 mg 0.8 mg 1.3 mg 0.8 mg 0.8 mg 7.4 mg
50		

55

Procedure:

9-cis Retinoic acid is mixed with anhydrous lactose and micro-crystalline cellulose.

The mixture is granulated in water with a solution/dispersion of polyvinylpyrrolidone, dl- α -Tocopherol and sodium ascorbate.

The granular material is mixed with magnesium stearate and afterwards pressed as kernels with 250 mg weight.

The kernels are film coated with a solution/suspension of above-mentioned composition.

10 Example 7

Sachet containing 50 mg active substance:

Composition:

15

20

25

9-cis Retinoic acid	50.0 mg
Lactose, fine powder	990.0 mg
Microcrystalline cellulose	1400.0 mg
Sodium Carboxymethyl-cellulose	14.0 mg
dl- α -Tocopherol	5.0 mg
Sodium ascorbate	20.0 mg
Polyvinylpyrrolidone K30	10.0 mg
Magnesium stearate	10.0 mg
Flavouring Agents	1.0 mg
(Fill weight of a sachet)	2500.0 mg

30 Procedure:

9-cis Retinoic acid is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose.

The mixture is granulated in water with a solution/dispersion of polyvinylpyrrolidone, dl- α -Tocopherol and sodium ascorbate.

35 The granule is mixed with magnesium stearate and flavoring agents.
It is filled into sachets of suitable size.

Claims

- 40 1. Pharmaceutical compositions containing 9-cis retinoic acid, a pharmaceutically acceptable salt or a pharmaceutically acceptable hydrolyzable ester thereof, and a therapeutically inert pharmaceutically acceptable carrier.
2. A composition as in claim 1 suitable for oral application.
- 45 3. A composition as in claim 1 suitable for topical application.
4. A composition as in claim 1 for the treatment of premalignant or precancerous epithelial lesions or epithelial tumors.
- 50 5. A composition as in claim 4 for the treatment of leukoplakias of the oral cavity.
6. A composition as in claim 4 for the treatment of epithelial tumors of the breast, cervix, prostate, skin, colon, bladder, esophagus, stomach, larynx, lung or oral cavity.
- 55 7. A composition as in claim 3 for the treatment of conditions associated with photodamaged skin.
8. A composition as in any one of claims 2 or 3 for reducing sebum secretion and acne symptoms.

9. A composition as in any one of claims 2 or 3 for the treatment of psoriasis.
10. A composition as in claim 2 comprising in a dosage unit from about 1 to about 50 mg of 9-cis retinoic acid, its pharmaceutically acceptable salts or pharmaceutically acceptable hydrolyzable esters.
- 5 11. A composition as in claim 3 wherein 9-cis retinoic acid, its pharmaceutically acceptable salts or pharmaceutically acceptable hydrolyzable esters is present in an amount of 0.01% to about 0.15% by weight.
- 10 12. The composition of claim 11, wherein said composition contained from about 0.02% to about 0.05% by weight of 9-cis retinoic acid, its pharmaceutically acceptable salts or pharmaceutically acceptable hydrolyzable esters.
- 15 13. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament.
14. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament suitable for oral application.
- 20 15. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament suitable for topical application.
16. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament for the treatment of premalignant or precancerous epithelial lesions
25 or epithelial tumors.
17. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament for the treatment of leukoplakias of the oral cavity.
- 30 18. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament for the treatment of epithelial tumors of the breast, cervix, prostate, skin, colon, bladder, esophagus, stomach, larynx, lung or oral cavity.
19. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament for the treatment of conditions associated with photodamaged skin.
35
20. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament for reducing sebum secretion and acne symptoms.
- 40 21. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament for the treatment of psoriasis.
22. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament suitable for oral application wherein a dosage unit of said
45 medicament comprises from about 1 to about 50 mg of active ingredient.
23. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament suitable for topical application wherein said medicament contains from about 0.01% to about 0.15% by weight of active ingredient.
- 50 24. 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for use as a medicament suitable for topical application wherein said medicament contains from about 0.02% to about 0.05% by weight of active ingredient.
25. The use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for the manufacture of a medicament for the treatment of premalignant or precancerous epithelial lesions or epithelial tumors.
55

26. The use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for the manufacture of a medicament for the treatment of leukoplakias of the oral cavity.
- 5 27. The use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for the manufacture of a medicament for the treatment of epithelial tumors of the breast, cervix, prostate, skin, colon, bladder, esophagus, stomach, larynx, lung or oral cavity.
- 10 28. The use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for the manufacture of a medicament for the treatment of conditions associated with photo-damaged skin.
- 15 29. The use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for the manufacture of a medicament for reducing sebum secretion and acne symptoms.
30. The use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for the manufacture of a medicament for the treatment of psoriasis.
- 20 31. The use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for the manufacture of a medicament for the treatment of the medical indications as defined in claims 25 to 30 wherein said medicament is suitable for oral application.
- 25 32. The use of 9-cis retinoic acid, its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters for the manufacture of a medicament for the treatment of the medical indications as defined in claims 25 to 30 wherein said medicament is suitable for oral application is suitable for topical application.
- 30 33. The use as in claim 31 wherein a dosage unit of said medicament contains from about 1 to about 50 mg of active ingredient.
- 35 34. The use as in claim 32 wherein said medicament contains from about 0.01% to about 0.15% by weight of active ingredient.
- 35 35. The use as in claim 32 wherein said medicament contains from about 0.02% to about 0.05% by weight of active ingredient.
- 40 36. The invention as hereinbefore described especially with reference to the Examples.

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 10 0257
Page 1

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)
X	DE-A-3 827 467 (L'OREAL) 23 February 1989 * claims 1,4,10,11,17 *	1,3-9, 11-24 25-36	A61K31/20 A61K31/07
P,X	CHEMICAL ABSTRACTS, vol. 118, no. 5, 1 February 1993, Columbus, Ohio, US; abstract no. 39207c, TOYODA HITOSHI ET AL. 'PREPARATION OF VITAMIN A ACID ESTER COMPOUNDS AS ANTITUMOR AGENTS AND ULCER THERAPEUTICS FOR SKIN AND DIGESTIVE TRACT' page 717 ;column 2 ; * abstract * & JP-A-04 244 076 (JPN. KOKAI TOKKO KOHO) 1 September 1992 ---	1-27, 31-36	
X	LEUKEMIA RESEARCH vol. 10, no. 6, 1986, pages 619 - 629 A. YEN ET AL 'RETINOIC ACID INDUCED HL-60 MYELOID DIFFERENTIATION: DEPENDENCE OF EARLY AND LATE EVENTS ON ISOMERIC STRUCTURE' * abstract * * page 622 - page 623 * * page 627 * ---	13-24 25-36	TECHNICAL FIELDS SEARCHED (Int. CL.5)
Y	WO-A-8 807 857 (DALTEX MEDICAL SCIENCES, INC.) 20 October 1988 * page 2-4 * * page 23-24; claims 1-3,6,7-9,12-15,18-19 *	28-31, 33,36	A61K
Y	WO-A-900 675 (MOLECULAR DESIGN INTERNATIONAL, INC.) 28 June 1990 * page 1 - page 4; claims 1-3,6 *	25, 27-29, 32,34-36	
The present search report has been drawn up for all claims			
Place of search THE HAGUE	Date of completion of the search 23 APRIL 1993	Examiner KRAUTBAUER B.	
CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document		
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background G : non-written disclosure P : intermediate document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 10 0257
Page 2

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claims	CLASSIFICATION OF THE APPLICATION (Int. Cl.s)						
Y	J. AM. ACAD. DERMATOL. vol. 6, 1982, pages 824 - 827 F.L. MEYSKENS 'STUDIES OF RETINOID IN THE PREVENTION AND TREATMENT OF CANCER' * the whole document *	25-27, 29-36 ---							
Y	THE LANCET vol. 2, 1980, pages 224 - 226 LEVINE ET AL. 'TOPICAL VITAMIN-A-ACID THERAPY FOR CUTANEOUS METASTATIC MELANOMA' * the whole document *	25-27, 31-36 ---							
Y	J. AM. ACAD. DERMATOL. vol. 9, no. 5, 1983, pages 797 - 805 W. BOLLAG ET AL. 'THE DEVELOPMENT OF RETINOID IN EXPERIMENTAL AND CLINICAL ONCOLOGY AND DERMATOLOGY' * the whole document *	25-27, 29-36 ---							
Y	JOURNAL OF CHROMATOGRAPHY vol. 227, no. 2, 1982, pages 471 - 484 F.M. VANE ET AL. 'DETERMINATION OF 13-CIS-RETINOIC ACID AND ITS MAJOR METABOLITE, 4-OXO-13-CIS-RETINOIC ACID, IN HUMAN BLOOD BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY' * page 471 *	25-36 -/-	TECHNICAL FIELDS SEARCHED (Int. Cl.s)						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>23 APRIL 1993</td> <td>KRAUTBAUER B.</td> </tr> </table> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>A : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	23 APRIL 1993	KRAUTBAUER B.
Place of search	Date of completion of the search	Examiner							
THE HAGUE	23 APRIL 1993	KRAUTBAUER B.							



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 10 0257
Page 3

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)
P, Y	<p>NATURE vol. 355, no. 6358, 23 January 1992, pages 359 - 361 A.A. LEVIN ET AL. '9-CIS RETINOIC ACID STEREOISOMER BINDS AND ACTIVATES THE NUCLEAR RECEPTOR RXRa' * abstract * * page 361 *</p> <p>-----</p>	25-36	
			TECHNICAL FIELDS SEARCHED (Int. CL.5)
<p>The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	23 APRIL 1993	KRAUTBAUER B.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			